BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2117268)

  • 1. Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
    Prezioso JA; Fitzgerald GB; Wick MM
    Pigment Cell Res; 1990; 3(2):49-54. PubMed ID: 2117268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cells.
    Prezioso JA; Epperly MW; Wang N; Bloomer WD
    Cancer Lett; 1992 Mar; 63(1):73-9. PubMed ID: 1555210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
    Prezioso JA; FitzGerald GB; Wick MM
    J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cells.
    Prezioso JA; Damodaran KM; Wang N; Bloomer WD
    Biochem Pharmacol; 1993 Jan; 45(2):473-81. PubMed ID: 8435097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione depletion increases tyrosinase activity in human melanoma cells.
    del Marmol V; Solano F; Sels A; Huez G; Libert A; Lejeune F; Ghanem G
    J Invest Dermatol; 1993 Dec; 101(6):871-4. PubMed ID: 7902381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.
    Prakash NJ; Sunkara PS; Sjoerdsma A
    Biochem Pharmacol; 1985 Jun; 34(11):1887-90. PubMed ID: 3924051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells.
    Benathan M; Alvero-Jackson H; Mooy AM; Scaletta C; Frenk E
    Melanoma Res; 1992 Dec; 2(5-6):305-14. PubMed ID: 1337997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of 4-hydroxyanisole and tyrosinase activity in variant cell lines of B16 melanoma.
    Thody AJ; Oliver I; Sherbet GV
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1879-84. PubMed ID: 2851444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of glutathione level in cultured human melanoma cells.
    Karg E; Brötell H; Rosengren E; Rorsman H
    Acta Derm Venereol; 1989; 69(2):137-41. PubMed ID: 2564231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of the depigmenting effect of hydroquinone by cystamine and buthionine sulfoximine.
    Bolognia JL; Sodi SA; Osber MP; Pawelek JM
    Br J Dermatol; 1995 Sep; 133(3):349-57. PubMed ID: 8546987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term buthionine-sulfoximine-mediated toxicity in cultured hepatoma cell lines.
    Dierickx PJ
    Res Commun Chem Pathol Pharmacol; 1990 Mar; 67(3):423-6. PubMed ID: 2160706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3,4-Dihydroxybenzylamine: an improved dopamine analog cytotoxic for melanoma cells in part through oxidation products inhibitory to dna polymerase.
    FitzGerald GB; Wick MM
    J Invest Dermatol; 1983 Feb; 80(2):119-23. PubMed ID: 6401786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-myelotoxic antitumour effects of L-dopa, buthionine sulphoximine and tamoxifen on neuroblastoma cells in vitro and in vivo.
    Busse E; Bartsch O; Kornhuber B
    J Cancer Res Clin Oncol; 1991; 117(5):449-53. PubMed ID: 1653780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
    Thrall BD; Raha GA; Springer DL; Meadows GG
    Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
    Kable EP; Favier D; Parsons PG
    Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice.
    Ishikawa M; Takayanagi Y; Sasaki K
    Res Commun Chem Pathol Pharmacol; 1990 Jan; 67(1):131-41. PubMed ID: 2326543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite regulation of tyrosinase and glutathione peroxidase by intracellular thiols in human melanoma cells.
    Benathan M
    Arch Dermatol Res; 1997 May; 289(6):341-6. PubMed ID: 9209680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
    Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells.
    Benathan M
    Melanoma Res; 1996 Jun; 6(3):183-9. PubMed ID: 8819121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-regulation of melanin precursors and tyrosinase in human pigment cells: roles of cysteine and glutathione.
    Benathan M; Virador V; Furumura M; Kobayashi N; Panizzon RG; Hearing VJ
    Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):981-90. PubMed ID: 10644002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.